Regeneron Antibody Cocktail a Priority for FDA with April Action Date

The U.S. Food and Drug Administration (FDA) has agreed to place Regeneron Pharmaceuticals, Inc.' Biologics License Application (BLA) for COVID-19 drug REGEN-COV under priority review and gave the company until April 13, 2022, to take action.